Clinical trials
Withdrawn Kidney Failure, Chronic trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
65 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 2 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 4 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 4 |
| 2013 | 5 |
| 2014 | 4 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 4 |
| 2019 | 8 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 5 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Withdrawn | 65 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Iperboreal Pharma Srl | 3 |
| Medical Components, Inc dba MedComp | 2 |
| Medical University of Graz | 2 |
| University of Alabama at Birmingham | 2 |
| University of California, San Francisco | 2 |
| University of Wisconsin, Madison | 2 |
| AbbVie | 1 |
| Albert Einstein College of Medicine | 1 |
| Apellis Pharmaceuticals, Inc. | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Kidney Failure, Chronic | 65 |
| Renal Insufficiency, Chronic | 7 |
| Cardiovascular Diseases | 4 |
| COVID-19 | 3 |
| Heart Failure | 3 |
| Hepatitis C | 3 |
| Kidney Diseases | 3 |
| Delayed Graft Function | 2 |
| Diabetes Mellitus | 2 |
| Diabetes Mellitus, Type 2 | 2 |
Trials
Showing 1 to 25 of 65. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.